Vertex Pharmaceuticals, Inc. (VRTX)
546.12
-11.84
(-2.12%)
USD |
NASDAQ |
Sep 04, 16:00
545.11
-1.01
(-0.18%)
After-Hours: 20:00
Vertex Pharmaceuticals Research and Development Expense (Quarterly) : 993.80M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 993.80M |
| March 31, 2026 | 961.60M |
| December 31, 2025 | 973.70M |
| September 30, 2025 | 977.70M |
| June 30, 2025 | 978.40M |
| March 31, 2025 | 999.50M |
| December 31, 2024 | 998.70M |
| September 30, 2024 | 890.90M |
| June 30, 2024 | 5.416B |
| March 31, 2024 | 865.90M |
| December 31, 2023 | 821.80M |
| September 30, 2023 | 861.70M |
| June 30, 2023 | 896.20M |
| March 31, 2023 | 1.090B |
| December 31, 2022 | 691.30M |
| September 30, 2022 | 674.00M |
| June 30, 2022 | 662.00M |
| March 31, 2022 | 603.10M |
| December 31, 2021 | 691.50M |
| September 30, 2021 | 493.75M |
| June 30, 2021 | 1.407B |
| March 31, 2021 | 455.97M |
| December 31, 2020 | 466.58M |
| September 30, 2020 | 493.50M |
| June 30, 2020 | 420.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 448.53M |
| December 31, 2019 | 480.01M |
| September 30, 2019 | 555.95M |
| June 30, 2019 | 379.09M |
| March 31, 2019 | 339.49M |
| December 31, 2018 | 437.88M |
| September 30, 2018 | 330.51M |
| June 30, 2018 | 337.53M |
| March 31, 2018 | 310.55M |
| December 31, 2017 | 306.66M |
| September 30, 2017 | 454.95M |
| June 30, 2017 | 289.45M |
| March 31, 2017 | 273.56M |
| December 31, 2016 | 248.45M |
| September 30, 2016 | 272.37M |
| June 30, 2016 | 271.01M |
| March 31, 2016 | 255.86M |
| December 31, 2015 | 310.43M |
| September 30, 2015 | 246.28M |
| June 30, 2015 | 223.86M |
| March 31, 2015 | 215.60M |
| December 31, 2014 | 201.46M |
| September 30, 2014 | 190.94M |
| June 30, 2014 | 224.78M |
| March 31, 2014 | 238.96M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.69B |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Sionna Therapeutics, Inc. | 21.86M |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Biogen, Inc. | 461.70M |